Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
3-YEAR FOLLOW-UP OF ACROMEGALIC PATIENTS TREATED WITH INTRAMUSCULAR SLOW-RELEASE LANREOTIDE
Autore:
CARON P; MORANGERAMOS I; COGNE M; JAQUET P;
Indirizzi:
CHU RANGUEIL,SERV ENDOCRINOL & MALAD METAB,1 AVE J POULHES F-31054 TOULOUSE FRANCE CHU RANGUEIL,DEPT ENDOCRINOL F-31054 TOULOUSE FRANCE CHU TIMONE,DEPT ENDOCRINOL MARSEILLE FRANCE
Titolo Testata:
The Journal of clinical endocrinology and metabolism
fascicolo: 1, volume: 82, anno: 1997,
pagine: 18 - 22
SICI:
0021-972X(1997)82:1<18:3FOAPT>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTINUOUS SUBCUTANEOUS INFUSION; SOMATOSTATIN ANALOG OCTREOTIDE; GROWTH-HORMONE RESPONSES; LONG-ACTING FORMULATION; SMS 201-995; PITUITARY-ADENOMAS; TERM TREATMENT; THERAPY; PHARMACOKINETICS; SMS-201-995;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
P. Caron et al., "3-YEAR FOLLOW-UP OF ACROMEGALIC PATIENTS TREATED WITH INTRAMUSCULAR SLOW-RELEASE LANREOTIDE", The Journal of clinical endocrinology and metabolism, 82(1), 1997, pp. 18-22

Abstract

Somatostatin analogs are an alternative treatment to pituitary surgery and radiotherapy in acromegalic patients. Recently, a depot long-lasting formulation of slow release (SR) lanrectide has been shown to be effective in the short-term control of GH hypersecretion in acromegalic patients. We report the long-term follow-up of a cohort of 22 acromegalic patients treated with SR lanreotide during 1-3 yr. Thirteen females and 9 males, age 51 +/- 3 yr, presented with macroadenomas (n = 12), microadenomas (n = 8), or empty sella (n = 2). Seven patients previously had undergone a partial surgical removal of their adenomas, and 21 of them has mean plasma GH levels less than 5 mu g/L during a previous octreotide treatment. According to GH values recorded after 3 months of twice monthly 30 mg SR lanreotide im injection, SR lanreotide was administered every 14 days (n = 13) or every 10 days (n = 9). At the6-month visit, mean GH values were 5 mu g/L or less in 68% and 2.5 mug/L or less in 27% of patients, and these results remained unchanged during the 1-3 yr follow-up period. During SR lanreotide treatment, the mean insulin-like growth factor I (IGF-I) concentrations remained inthe normal range in 63% of patients. No escape from the treatment occured in any of the cases. A significant decrease of the pituitary tumor volume was observed in 3 (13%) patients. The main side effect consisted of minor digestive problems during 48 h after each injection and was reported by 13 patients. Biannual gallbladder echographies revealedthe occurence of gallstones in 4 (18%) patients. In conclusion, thesedata confirms the efficacy and the tolerance of the long-term SR lanreotide administration (30 mg im every 10-14 days) in the control of acromegaly.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 15:52:46